anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used in dermatovenerology when treating microbial eczema. What is presented is a background of traditional treatment of microbial eczema, including drug-induced exposure with antihistamine, antibacterial, glucocorticosteroid preparations, detoxification therapy, additionally prescribe combined effect of Dimephosfon preparation and local exposure with Ultratone apparatus. Ultratonotherapy is performed in the following modes: output voltage 3.0 kV, frequency of sinusoidal output voltage 22 kHz, with a clearance above lesion 1–2 mm through a tissue napkin, with exposure of 10–20 seconds per 1 cmarea of focus. Patient receives 15 ml of 15 % aqueous solution of Dimephosfon on a background of ultratonoter therapy three times. Ultratonotherapy is performed 1 hour after the first dose of Dimephosfon. Therapeutic course makes 10 days. Repeated therapeutic courses are prescribed 25–30 days after the indications.EFFECT: method enables reducing the length of the systemic and topical application of hormonal and antibacterial preparations, reducing the rehabilitation period of the patients, achieving a longer remission, eliminating cosmetic defects and improving the patients' quality of life.1 cl, 1 ex
1,167,088. Nitrofuran derivatives. PHARMACIA A.B. 13 Feb., 1967 [14 Feb., 1966], No. 6703/67. Heading C2C. Novel compounds of the formula wherein n is 0 or 1 and A represents a radical having the formula in which each of R 1  and R 2  is C 1-3  alkyl or allyl, X is oxygen, sulphur or =NR 4 , wherein R 4  is hydrogen, C 1-3  alkyl or allyl and Y is sulphur or = NR 3 , wherein R 3  is C 1-3  alkyl, and their therapeutically acceptable salts, are prepared by reacting a compound of the formula with a compound of the formula H 2 =A or a reactive derivative thereof, at a temperature of 20‹ to 120‹ C. in the presence of a solvent. The compounds wherein A represents a radical of Formula (II) in which X is oxygen, are also prepared from compounds of the same formula wherein X represents =NR 4  in which R 4  is C 1-3  alkyl or allyl, by treatment with hydrolysing media. The compounds wherein n is 0 and A is a radical of Formula (II) in which Y is sulphur and X is =NR 4  are also prepared by reacting a compound of formula wherein R is C 1-6  alkyl, with a compound of formula R 4 -NH-CS-NH-R 1 . The novel compounds have antibacterial and antimycotic properties.
PURPOSE:To accelerate the growth of a new bone by uniformly and rapidly precipitating amorphous calcium phosphate type compound having good biocompatibility on the contact surface with the bone of a living body by applying superplastic processing to ceramics containing CaO and SiO2 as essential components and capable of forming the calcium phosphate compound. CONSTITUTION:0.05-800 pts.wt. of a silica supply component expressed in terms of SiO2, 0.05-600 pts.wt. of a calcium oxide supply component as CaO and at least one component selected from 0.05-600 pts.wt. of an alumina supply component expressed in terms of Al2O3 and 0.05-600 pts.wt. of a magnesia supply component expressed in terms of MgO are pref. used per 100 pts.wt. of a matrix material. The use ratio of these components is set so that silica is 0.5-20mol, alumina is 0.1-20mol and magnesia is 0.1-20mol when calcium oxide is 1mol.
After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
Pregnancy is a time of increased vulnerability to psychopathology, yet limited work has investigated the extent to which variation in psychopathology during pregnancy is shared and unshared across syndromes and symptoms. Understanding the structure of psychopathology during pregnancy, including associations with childhood experiences, may elucidate risk and resilience factors that are transdiagnostic and/or specific to particular psychopathology phenotypes. Participants were 292 pregnant individuals assessed using multiple measures of psychopathology. Confirmatory factor analyses found evidence for a structure of psychopathology consistent with the Hierarchical Taxonomy of Psychopathology (HiTOP). A common transdiagnostic factor accounted for most variation in psychopathology, and both adverse and benevolent childhood experiences (ACEs and BCEs) were associated with this transdiagnostic factor. Furthermore, pregnancy-specific anxiety symptoms most closely reflected the dimension of Fear, which may suggest shared variation with manifestations of fear that are not pregnancy-specific. ACEs and BCEs also linked to specific prenatal psychopathology involving thought problems, detachment, and internalizing, externalizing, antagonistic, and antisocial behavior. These findings extend the dimensional and hierarchical HiTOP model to pregnant individuals and show how maternal childhood risk and resilience factors relate to common and specific forms of psychopathology during pregnancy as a period of enhanced vulnerability.
This is a randomized, placebo-controlled, double-blinded study to assess the safety and pharmacokinetics of CNTO 136. In a randomized trial, study medication (CNTO 136 or placebo) is assigned by chance. Double-blinded means that neither the investigator nor the volunteer know which of the study medication they have been assigned to receive. Pharmacokinetics is the study of levels of CNTO 136 circulating in your blood over time. The study population will all be male and consist of 30 Japanese and 30 Caucasian volunteers. Three dose levels of study agent will be assessed. Participants will be required to stay at the research center after study agent administration for the inpatient portion of the study and then required to return for out-patient visits. One of 3 dose levels of CNTO 136 will be given just under the skin (subcutaneous (SC)). The length of this study will be about 20 weeks.
A method of assessing a medical malady. The method includes receiving response data. The response data is stored as a record in a data structure. A first data subset of select patient records is created including individuals who indicated having an improved health status after being treated for a particular malady. At least one commonality or difference is identified among the personal information. A second data subset of at least one identified commonality or identified difference is created. The first data subset is analyzed with respect to the second data subset to determine whether at least one identified commonality or identified difference is relevant to the improved health status of one or more individuals. A prediction is output of at least one of the identified commonality or the identified difference as a potential treatment for the particular malady for one or more of the plurality of individuals.
In Japan, liver biopsies were previously crucial in evaluating the severity of hepatitis caused by the hepatitis C virus (HCV) and diagnosing HCV-related hepatocellular carcinoma (HCC). However, due to the development of effective antiviral treatments and advanced imaging, the necessity for biopsies has significantly decreased. This change has resulted in fewer chances for diagnosing liver disease, causing many general pathologists to feel less confident in making liver biopsy diagnoses. This article provides a comprehensive overview of the challenges and potential solutions related to liver biopsies in Japan. First, it highlights the importance of considering steatotic liver diseases as independent conditions that can coexist with other liver diseases due to their increasing prevalence. Second, it emphasizes the need to avoid hasty assumptions of HCC in nodular lesions, because clinically diagnosable HCCs are not targets for biopsy. Third, the importance of diagnosing hepatic immune-related adverse events caused by immune checkpoint inhibitors is increasing due to the anticipated widespread use of these drugs. In conclusion, pathologists should be attuned to the changing landscape of liver diseases and approach liver biopsies with care and attention to detail.
PROBLEM TO BE SOLVED: To provide an agent for preventing periodontal disease from a new point of view having advantage such as lower appearance risk of resistant bacterium comparing to existing antibacterial agent or the like.SOLUTION: There is provided a composition for oral cavity having a biofilm formation inhibitory effect which contains cold water extract of Brassica rapa var. nipposinica. Preferably, there is provided a gargle for suppressing biofilm formation containing cold water extract of Brassica rapa var. nipposinica. Preferably, there is provided a toothpaste for suppressing biofilm formation containing cold water extract of Brassica rapa var. nipposinica. Preferably, there is provided an inhalant for suppressing biofilm formation containing cold water extract of Brassica rapa var. nipposinica.SELECTED DRAWING: Figure 1
BACKGROUND: Oral squamous cell carcinoma (OSCC) continues to prevail as a highly prevalent cancer in Southeast Asia and causes a significant health burden. Stratification of patients with high risks of recurrence and mortality is important in the planning of treatment and surveillance.
METHODS: Formalin-fixed paraffin-embedded (FFPE) tissues of OSCC were immuno-stained and analyzed for p16 expression. Risk factors and clinical parameters of OSCC patients were collected and compared to identify factors associated with recurrences and overall survival.
RESULTS: After a median follow-up of 32 months, OSCC recurrences and mortality were observed in 82% and 78% of patients (N=60), respectively. Larger and more extensive tumors (T3 and T4) were significantly associated with both recurrences and cancer-associated mortality (OR = 3.967, 95% CI = 1.007-15.618 and OR = 5.885, 95% CI = 1.541-22.47, respectively). P16INK4A positive staining was found in 31% of tumors. Patients with p16INK4A positive staining were significantly associated with better recurrence-free and overall survivals (medians of recurrence-free survivals were 31.2 vs 19.0 months, P=0.038 and overall survivals were 39.0 vs 28.8 months,  P=0.048; respectively). Some other clinical characteristics including early stages, non-keratinizing tumors, negative cervical node, and free-surgical margin were significantly associated with better recurrence-free and overall survivals (log-rank tests, P<0.05).
CONCLUSION: P16INK4A positive staining, early stages, negative cervical lymph node infiltration, and free-surgical margins are associated with better prognosis in OSCC patients. The study emphasizes the importance of early detection and the potential use of p16INK4A and other clinical variables to stratify OSCC patients with high risks of recurrence and worse overall survivals.
BACKGROUND: Frequent consumption of Energy Drinks (EDs) is associated with numerous health problems, including overweight and obesity, particularly among children and adolescents. The extensive promotion, wide accessibility, and relatively low cost of EDs have significantly increased their popularity among this age group. This paper examines policies/programs that, directly and indirectly, contribute to reducing ED consumption in children and adolescents and shares global experiences to help policymakers adopt evidence-based policies.
METHODS: A systematic search was performed using PubMed, Scopus, and Web of Science databases from January 2000 to June 2024, along with reputable international organization websites, to find literature on policies aimed at reducing ED consumption among children and adolescents. All sources meeting the inclusion criteria were included without restrictions. Titles and abstracts were initially screened, followed by a full-text review. After evaluating the quality of the selected studies, data were extracted and, along with information from the selected documents, compiled into a table, detailing the country, policy type, and the effectiveness and weaknesses of each policy.
RESULTS: Out of 12166 reviewed studies and documents, 84 studies and 70 documents met the inclusion criteria. 73 countries and territories have implemented policies like taxation, sales bans, school bans, labeling, and marketing restrictions on EDs. Most employ fiscal measures, reducing consumption despite enforcement challenges. Labeling, access restrictions, and marketing bans are common but face issues like black markets.
CONCLUSION: This scoping review outlines diverse strategies adopted by countries to reduce ED consumption among children and teenagers, such as taxation, school bans, sales restrictions, and labeling requirements. While heightened awareness of ED harms has reinforced policy efforts, many Asian and African nations lack such measures, some policies remain outdated for over a decade, and existing policies face several challenges. These challenges encompass industry resistance, governmental disagreements, public opposition, economic considerations, and the intricacies of policy design. Considering this, countries should tailor policies to their cultural and social contexts, taking into account each policy's strengths and weaknesses to avoid loopholes. Inter-sectoral cooperation, ongoing policy monitoring, updates, and public education campaigns are essential to raise awareness and ensure effective implementation.
Nine primary healthcare centers in the Bhaktapur district of Nepal will be selected as an intervention group. The centers will be assessed for the baseline PEN service evaluation and then will be provided the peer coaching and clinical audit sensitization within 6 months of the intervention period. At the end of one year, an evaluation will be performed again in the centers for any change in the PEN services.
The invention provides ginkgo leaf extract eye gel water for improving eye skin. Comprises the following components in parts by weight: 3-10 parts of ginkgo leaf extract, 0.0001-0.0005 part of skin conditioner, 2-8 parts of humectant, 3-12 parts of thickener, 0.5-2 parts of solubilizer, 0.2-0.5 part of preservative and 0.001-0.003 part of aromatic. The invention has scientific mixture ratio, and the ginkgo leaf extract has obvious effect on preventing and smoothing eye bags or black eyes. The product is jelly aqua. Is fresh and easy to absorb, and can not cause burden to eye skin. The invention has the purposes of inhibiting the loss of collagen elastic fibers, promoting blood circulation, promoting skin metabolism, and preventing and smoothing eye bags or black eyes, and has no irritation to the skin. The preparation method provided by the invention has the advantages of simple process, controllable conditions and stable process, and is suitable for industrial production.
Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
The MME intervention arm will complete our 8-session intervention, weekly for 60-70 minutes per session. Homework will be assigned each week and reviewed the next session. Certificates will be issued to participants who complete the intervention. Fidelity assessments for each session will be evaluated by local research personnel.
Long-stay intensive care unit (ICU) patients, or children who require prolonged hospitalization in the pediatric ICU (PICU), represent a minority of PICU patients but have a disproportionate impact on hospital resources and unfavorable outcomes, including morbidity, mortality, and repeated critical illness. These patients and their families have multifaceted needs (eg, tailored communication) that pose unique challenges to PICU providers and the parent-provider relationship. These experiences and needs are compounded and complicated by the transitory care that is typically provided by PICU. This transitory care may contribute to 1) patient/family dissatisfaction; 2) ineffective passing of important information day to day and week to week; and 3) delayed decision-making. These latter two potential consequences may, in turn, contribute to prolonged length of stay (LOS).

For these reasons, the investigators propose a randomized control trial to test whether primary intensivists and primary nurses can decrease PICU LOS for long-stay patients. A primary intensivist is one that remains a consistent physician-presence for the patient/family and PICU team throughout the child's PICU stay, despite changes in the intensivist(s) who orchestrates day-to-day management. Primary nurses are a team of PICU nurses who provide the all/most of the bedside care to the child. The investigators hypothesize that the long-stay PICU patients who are randomized to receive primary intensivists and nurses will have a statistically lower LOS than those patients who do not.
OBJECTIVE: Multiple sclerosis (MS) is a chronic central nervous system disease whose white matter lesion origin remains debated. Recently, we reported subtle changes in the MS normal appearing white matter (NAWM), presenting with an increase in myelin blisters and myelin protein citrullination, which may recapitulate some of the prodromal degenerative processes involved in MS pathogenesis. Here, to clarify the relevance of these changes for subsequent MS myelin degeneration we explored their prevalence in WM regions characterized by subtly reduced myelination (dubbed as micro-diffusely abnormal white matter, mDAWM).
METHODS: We used an in-depth (immuno)histochemistry approach in 27 MS donors with histological presence of mDAWM and 5 controls. An antibody panel against degenerative markers was combined and the presence of myelin/axonal aberrations was analyzed and compared with the NAWM from the same cases/slices/regions.
RESULTS: mDAWM-defined areas exhibit ill-defined borders, no signs of Wallerian degeneration, and they associate with visible veins. Remarkably, such areas present with augmented myelin blister frequency, enhanced prevalence of polar myelin phospholipids, citrullination, and degradation of myelin basic protein (MBP) when compared with the NAWM. Furthermore, enhanced reactivity of microglia/macrophages against citrullinated MBP was also observed in this tissue.
INTERPRETATION: We report a new histologically defined early phase in MS lesion formation, namely mDAWM, which lacks signs of Wallerian pathology. These results support the prelesional nature of the mDAWM. We conceptualize that evolution to pathologically evident lesions comprises the previously documented imbalance of axo-myelinic units (myelin blistering) leading to their degeneration and immune system activation by released myelin components.
We hope to enroll a total of 1900 participants, 950 in each arm, over the next 2 years. One arm will be the telemonitoring group and one arm will be the standard of care group. Participants will be in the study for 30 days. Participants in the telemonitoring group will receive a Telestation, blood pressure monitor, and pulse oximeter. If the participant also has congestive heart failure, they will receive a scale. All of these vital measurements are to be taken on a daily basis along with survey questions on how the patient feels. If set parameters are out of the normal range, a flag will trigger that requires follow up/intervention from a nurse by telephone. In some cases, the participant might need to come back in to see a physician through the outpatient clinic. The participant in the standard of care group will be contacted via phone 30 days after discharge to learn if they were readmitted to any hospitals or had any emergency room visits during the past 30 days. This data will be collected via Philips software and also entered into the RedCap database here at Mayo Clinic.
Dendrobium nobile polygonum multiflorum thunb capsules for auxiliary lipid-lowering and method for preparing the same. The inventioin relates to a health care food for auxiliary lipid-lowering. The invention is prepared by mixing dendrobium nobile and polygonum multiflorum thumb together uniformly, and weight parts of the mixture is: dendrobium nobile 2-6 parts, polygonum multiflorum thumb 2-6 parts. The functional food combines the herb and food homologous ziyin hematinic reasonably and organically to health care food with prominent health care efficacy, which has obvious improvement in a series of symptoms caused by high-lipid. Common lipid-lowering products have damage or side effect on the liver and kidney stomach. The dendrobium nobile efficacy of tonifying the liver reinforcing the stomach strengthing the kidney, remedying shortage of other lipid-lowering products. The invention can resolve the current problems and eliminate root causes.
The invention discloses a tuberculosis-dispelling pill for treating tuberculosis. The pill is prepared by smashing decoction pieces of 24-25 traditional Chinese medicines comprising pseudo ginseng, lily, fritillaria cirrhosa, radix ophiopogonis, honeysuckle flower, balloonflower root, radix scrophulariae, common hogfenneI root, selfheal, and the like, sieving, fully mixing to obtain a pill made with water, and drying at a low temperature. The pill is a pure traditional Chinese medicine preparation, and has characteristics of wide medicine sources, easily available raw materials, simple process, convenient medicine taking, definite curative effects, and no damage, side effects or toxic effects to live and kidney. Through clinical observation, after taking of the pill, the body weight is obviously increased, immunity is boosted, focuses and cavities are self-absorbed, and symptoms are eliminated completely. Compared with the prior art, the pill has advantages of short curative course, rapid production of desired effects, no relapse, obvious curative effects for drug-resistant, allergic and refractory pulmonary tuberculosis, and obvious curative effects for scrofula, bone tuberculosis and tuberculosis of lumbar spine. The pill is an ideal anti-tuberculosis medicine at present and has value for wide popularization.
Topiramate is not approved for the treatment of obesity. This double-blind, placebo controlled study investigates the effect of topiramate on insulin sensitivity in overweight or obese patients with Type 2 Diabetes. After a screening phase, patients are randomized to receive either topiramate (96 milligrams\[mg\] twice daily) or placebo for 9 months in the double-blind phase. After 9 months, patients have the option to continue in the open-label phase and receive treatment with topiramate for 1 year. Patients in the placebo group then receive topiramate with dosage increasing gradually to 96 mg twice daily, with the option of increasing to 256 mg twice daily. Patients in the topiramate group continue with the maintenance dose received during the double-blind phase, with the option of increasing to 256 mg twice daily. Assessments of effectiveness made monthly include insulin sensitivity, body composition (as measured by computed tomography \[CT\]), body weight and Body Mass Index (BMI), waist and hip circumferences, fasting lipid profile, fasting glucose and hemoglobin type A1c (HbA1c) levels, and blood pressure. Safety evaluations, including incidence of adverse events, clinical laboratory results, vital signs, and electrocardiograms \[ECGs\]), are performed throughout the study. The study hypothesis is that topiramate will improve insulin sensitivity in type 2 diabetic patients and will be well tolerated. Patients will be randomized to receive 192 mg/day (96mg twice daily) of topiramate, or placebo, per mouth for 9 months, with an option of topiramate treatment increasing to 256mg/day both groups during the extension period of 1 year.